Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,346 result(s) found. Displaying page 1,476 of 2,218.
    «« First « Previous 1472  1473  1474  1475  1476  1477  1478  1479  1480  Next» Last»»
    EudraCT Number: 2007-006738-33 Sponsor Protocol Number: CL-1205 Start Date*: 2008-03-14
    Sponsor Name:NatImmune A/S
    Full Title: bLAC - A phase II double-blind, placebo controlled, clinical proof of concept trial of the efficacy of 8 weeks treatment of cutaneous warts with bLAC in immune suppressed, kidney transplanted patients
    Medical condition: Cutaneous wart lesions on hands and/or feet at immune suppressed, kidney transplanted patients.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010115 Common warts LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-018189-36 Sponsor Protocol Number: 0908143 Start Date*: 2010-05-17
    Sponsor Name:CHU Saint-Etienne
    Full Title: Prévention chez le receveur avec néphropathie à IgA primaire (NIGA) de la Récidive Après Transplantation rénale: ATG-F versus Basiliximab, comme traitements immunosuppresseurs d’induction. Etude ...
    Medical condition: IgA glomerulonephritis and first transplant
    Disease: Version SOC Term Classification Code Term Level
    12.1 10018367 Glomerulonephritis chronic LLT
    12.1 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016996-31 Sponsor Protocol Number: P09-004 Start Date*: 2010-06-28
    Sponsor Name:Upsher-Smith Laboratories, Inc.
    Full Title: A Randomized, Multicenter, Double-Blind, Placebo–Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients with Refractory Partial-O...
    Medical condition: Refractory partial-onset seizures with or without secondary generalization
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10056209 Partial seizures with secondary generalisation PT
    14.0 10029205 - Nervous system disorders 10034090 Partial seizures, complex LLT
    14.0 10029205 - Nervous system disorders 10040703 Simple partial seizures PT
    14.0 10029205 - Nervous system disorders 10048674 Partial seizures with secondary generalization LLT
    14.0 10029205 - Nervous system disorders 10010145 Complex partial seizures PT
    14.0 10029205 - Nervous system disorders 10034091 Partial seizures, simple LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) GR (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002177-20 Sponsor Protocol Number: RLM-MD-02 Start Date*: 2018-11-06
    Sponsor Name:Allergan Ltd.
    Full Title: A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) LV (Prematurely Ended) HU (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Prematurely Ended) AT (Completed) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004106-16 Sponsor Protocol Number: AC-052-375 Start Date*: Information not available in EudraCT
    Sponsor Name:Actelion pharmaceuticals Ltd
    Full Title: A randomized, prospective, double-blind, placebo-controlled, group sequential multicenter study to assess efficacy, safety, and tolerability of the pediatric formulation of bosentan in children wit...
    Medical condition: Pulmonary arterial hypertension (PAH) in children
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064908 Associated with (APAH) LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064909 Idiopathic (IPAH) LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064910 Familial (FPAH) LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing) FR (Ongoing) PT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-000440-18 Sponsor Protocol Number: CD-TCR-001 Start Date*: 2017-12-19
    Sponsor Name:Medigene AG
    Full Title: A Phase I/II, Open-Label, Non-Randomized, Multicentre, Dose-Escalation Clinical Trial with Control Group to Evaluate the Safety, Feasibility and Preliminary Efficacy of PRAME TCR Modified T Cells, ...
    Medical condition: High Risk Myeloid Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028557 Myeloid leukemia, acute LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003604-12 Sponsor Protocol Number: ITM201902 Start Date*: 2020-01-15
    Sponsor Name:Institute of Tropical Medicine
    Full Title: Evaluation of a chlorhexidine mouthwash for the eradication of asymptomatic pharyngeal Neisseria gonorrhoeae infection
    Medical condition: asymptomatic pharyngeal Neisseria gonorrhoeae (NG)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004862 10051970 Neisseria gonorrhoeae infection LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003018-14 Sponsor Protocol Number: CLL7 Start Date*: 2006-03-02
    Sponsor Name:AKH Vienna
    Full Title: Randomized phase III trial comparing early treatment with fludarabine, cyclophosphamide + rituximab versus deferred treatment in untreated Binet stage A patients with high risk of progression CLL 7...
    Medical condition: chronic lymphocytic leukaemia (CLL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005678-36 Sponsor Protocol Number: 06-APR-02 Start Date*: 2008-07-03
    Sponsor Name:CHU de Nice
    Full Title: Oral alendronate for osteoporosis treatment in non-walking children with cerebral palsy
    Medical condition: osteoporosis treatment in non-walking children with cerebral palsy
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003564-19 Sponsor Protocol Number: RB 08.058 Start Date*: 2009-03-10
    Sponsor Name:CHU de Brest
    Full Title: Traitement de la péricardite aiguë bénigne : Aspirine en cure courte versus traitement prolongé. Essai contrôlé multicentrique en double aveugle de non-infériorité
    Medical condition: La péricardite aigüe
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000781-23 Sponsor Protocol Number: GEN207 Start Date*: 2008-06-09
    Sponsor Name:Genmab A/S
    Full Title: An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination wi...
    Medical condition: Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum based Chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023860 Laryngeal squamous cell carcinoma stage III LLT
    9.1 10023861 Laryngeal squamous cell carcinoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004666-15 Sponsor Protocol Number: TMC-MDC-11-01 Start Date*: 2012-04-03
    Sponsor Name:The Medicines Company
    Full Title: A Phase II, double-blind, parallel group, dose-selection study to compare antifibrinolytic MDCO-2010 vs. placebo and tranexamic acid in reducing blood loss in patients undergoing primary cardiac su...
    Medical condition: Primary cardiac surgery involving cardiopulmonary bypass
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004826-87 Sponsor Protocol Number: NONSTOP Start Date*: 2012-06-08
    Sponsor Name:Fundacion Progreso y Salud
    Full Title: Randomized multicentric open-label phase III clinical trial to evaluate the efficacy of continual treatment versus discontinuation based in the presence of prodromes in a first episode of non-affe...
    Medical condition: First-episodes of non-affective psychosis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    14.1 10037175 - Psychiatric disorders 10038631 Residual schizophrenia, in remission LLT
    14.1 10042613 - Surgical and medical procedures 10065155 Treatment withdrawal LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004912-30 Sponsor Protocol Number: aprepitant1 Start Date*: 2008-07-31
    Sponsor Name:Karolinska Institutet
    Full Title: Modulation of opiate reward by NK1 antagonism: A laboratory based proof of concept study
    Medical condition: opiate abuse
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039004 Reversal of opiate activity LLT
    9.1 10012346 Dependence on opiates LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003019-47 Sponsor Protocol Number: SPD489-329 Start Date*: 2012-02-10
    Sponsor Name:Shire Development Inc
    Full Title: A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With R...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) EE (Prematurely Ended) FI (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004211-42 Sponsor Protocol Number: POL6326-009 Start Date*: 2020-03-06
    Sponsor Name:Polyphor Ltd.
    Full Title: An International, Phase 3, Multicenter, Randomized, Open-Label Trial Comparing Balixafortide in combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or ...
    Medical condition: Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002646-38 Sponsor Protocol Number: TMC278-TiDP6-C209 Start Date*: 2008-07-24
    Sponsor Name:Tibotec Pharmaceuticals Limited
    Full Title: A Phase III, randomized, double-blind trial of TMC278 75 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricit...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) AT (Completed) FR (Completed) DK (Completed) ES (Completed) GB (Completed) PT (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005405-37 Sponsor Protocol Number: NH19960 Start Date*: 2006-06-28
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapy
    Medical condition: Anemic patients undergoing chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) BE (Completed) ES (Completed) CZ (Completed) EE (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-006785-29 Sponsor Protocol Number: AC-054-302 Start Date*: 2009-09-15
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-caus...
    Medical condition: Indication: Subarachnoid aneurysmal hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    11 10042316 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) FI (Prematurely Ended) AT (Prematurely Ended) BE (Completed) CZ (Completed) FR (Completed) DE (Completed) SI (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004219-75 Sponsor Protocol Number: EMR200048-052 Start Date*: 2008-05-27
    Sponsor Name:Merck KGaA
    Full Title: Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for su...
    Medical condition: Advanced esophago-gastric cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Completed) BE (Prematurely Ended) HU (Completed) FR (Completed) AT (Completed) ES (Prematurely Ended) NL (Completed) PT (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended) BG (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1472  1473  1474  1475  1476  1477  1478  1479  1480  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 29 07:49:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA